Advertisement
Document › Details
Themis Bioscience GmbH. (6/11/18). "Press Release: Themis Receives EMA PRIME Designation for Chikungunya Vaccine". Vienna.
Region | EU (European Union) | |
Organisation | Themis Bioscience GmbH | |
Group | Merck (US) (MSD) (Group) | |
Organisation 2 | EMA (European Medicines Agency) | |
Group | EU (govt) | |
Product | vaccine_o | |
Product 2 | clinical research | |
Person | Tauber, Erich (Themis Bioscience GmbH 201505 CEO) | |
Themis announced today that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation to its most advanced program in development, a vaccine to prevent chikungunya fever. The PRIME scheme is designed to provide enhanced regulatory support for the development of medicines that target an unmet medical need. Chikungunya is a mosquito-transmitted disease that can have debilitating long-term effects and has no current treatment or prevention options. Themis’ vaccine candidate has shown excellent safety and immune-response data in clinical testing to date. Final results of a large dose-confirmation Phase 2 trial are expected in mid-2018. Additional Phase 2 trials are underway, totaling over 600 study volunteers in the US, EU and Central America.
“Being accepted into the PRIME scheme recognizes the potential of our program and the important endeavor of preventing chikungunya, a severe disease with global outbreak potential and no available treatments,” said Dr. Erich Tauber, CEO of Themis. “As we near the data read-out from our Phase 2 trial, we are currently gearing up for Phase 3 manufacturing and continuing interactions with the regulatory agencies will support a streamlined review and development process.”
The PRIME initiative was launched by EMA in 2016 to facilitate the development of medicines that target an important unmet medical need and may offer a major therapeutic advantage or benefit to patients without treatment options. These medicines are considered priority medicines within the European Union (EU). PRIME offers enhanced support to medicine developers to strengthen clinical trial designs, facilitate the generation of high-quality data and enable accelerated assessment of medicine applications.
About Themis
Themis Bioscience is developing urgently needed vaccines to prevent death and disability around the world. We lead in the development of a vaccine against chikungunya, a serious debilitating disease with global outbreak potential. Our innovation in vaccine technology has created a powerful platform and a growing pipeline addressing a broad range of infectious diseases. Together with industrial and academic leaders we work to prevent illness across the globe. For more information, visit http://www.themisbio.com.
Record changed: 2023-06-05 |
Advertisement
More documents for Merck (US) (MSD) (Group)
- [1] Owkin. (12/19/23). "Press Release: Owkin Enters Collaboration Agreement with MSD to Develop AI-powered Diagnostics for Cancer"....
- [2] Merck & Co., Inc.. (11/21/23). "Press Release: Merck to Acquire Caraway Therapeutics, Inc.". Rahway, NJ & Cambridge, MA....
- [3] Merck & Co., Inc.. (10/19/23). "Press Release: Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs". Basking Ridge, NJ & Rahway, NJ....
- [4] AiCuris Anti-infective Cures AG. (8/23/23). "Press Release: AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of Prevymis (letermovir) in Second Indication". Wuppertal....
- [5] Anavo Therapeutics B.V.. (5/2/23). "Press Release: Anavo Therapeutics Extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic". Leiden & Heidelberg....
- [6] Proxygen GmbH. (4/5/23). "Press Release: Proxygen Announces Collaboration and License Agreement with MSD". Vienna....
- [7] Merck & Co., Inc.. (12/21/22). "Press Release: Lynparza (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer". Rahway, NJ....
- [8] Novartis AG. (9/1/22). "Press Release: Novartis Appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., Steps Down from the Executive Committee of Novartis". Basel....
- [9] Moderna, Inc.. (4/27/22). "Press Release: Arpa Garay Joins Moderna as Chief Commercial Officer". Cambridge, MA....
- [10] Catalym GmbH. (5/4/21). "Press Release: Catalym Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer". Munich....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top